SCHEMBL30325672

SCHEMBL30325672

C=C(F)C(=O)Nc1ccc(-c2nn3ncnc(N)c3c2-c2ccc(C(=O)NC3(C)CC3)c(OC)c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 2/20 0.36
▸ CSNK2A2 P19784 1/20 0.36
▸ CSNK2A1 P68400 1/20 0.36
▸ BTK Q06187 9/20 0.34
▸ EGFR P00533 4/20 0.34
▸ TEC P42680 4/20 0.33
▸ TXK P42681 4/20 0.33
▸ BMX P51813 4/20 0.33
▸ PLK4 O00444 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ DAPK3 O43293 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ PAK4 O96013 1/20 0.32
▸ CHEK2 O96017 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ NTRK1 P04629 1/20 0.32
▸ INSR P06213 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ FYN P06241 1/20 0.32
▸ CSF1R P07333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325631 0.93 TNK2 (0.35) TNK2CSNK2A2CSNK2A1BTKEGFR
SCHEMBL30325885 0.92 RET (0.35) TNK2CSNK2A2CSNK2A1RET
SCHEMBL30325706 0.91 CSNK2A2 (0.35) TNK2CSNK2A2CSNK2A1BTKEGFR
SCHEMBL31213926 0.91 CSNK2A2 (0.36) TNK2CSNK2A2CSNK2A1BTKEGFR
SCHEMBL30326052 0.90 TNK2 (0.37) TNK2CSNK2A2CSNK2A1BTKEGFR
SCHEMBL30326168 0.90 CSNK2A2 (0.35) TNK2CSNK2A2CSNK2A1BTKEGFR
SCHEMBL29265816 0.89 GAK (0.38) TNK2CSNK2A2CSNK2A1BTKEGFR
SCHEMBL30325990 0.88 MAPT (0.41) TNK2BTKEGFRPLK4AURKA
SCHEMBL30326178 0.88 CSNK2A2 (0.43) TNK2CSNK2A2CSNK2A1BTKEGFR
SCHEMBL30325946 0.88 CSNK2A2 (0.49) TNK2CSNK2A2CSNK2A1BTKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 TNK2 493/4885CSNK2A2 862/4885CSNK2A1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback